Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16832564 | 0.87 | RAB9A (0.77) | RAB9ANPC1KDM4ELMNAMAPK1 | |
| SCHEMBL19762436 | 0.84 | RAB9A (0.58) | RAB9ANPC1KDM4ELMNAMAPK1 | |
| SCHEMBL16832143 | 0.81 | RAB9A (0.56) | RAB9ANPC1KDM4ELMNAMAPK1 | |
| SCHEMBL20281262 | 0.79 | GAA (0.53) | KDM4EL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL23486567 | 0.79 | PDE4D (0.55) | RAB9ANPC1KDM4ELMNAMAPK1 | |
| SCHEMBL18483483 | 0.79 | RAB9A (0.61) | RAB9ANPC1KDM4ELMNAMAPK1 | |
| SCHEMBL9353161 | 0.79 | RAB9A (0.49) | RAB9ANPC1KDM4ELMNAMAPK1 | |
| SCHEMBL16855655 | 0.76 | RAB9A (0.58) | RAB9ANPC1KDM4ELMNAMAPK1 | |
| SCHEMBL19762437 | 0.76 | RAB9A (0.61) | RAB9ANPC1KDM4ELMNAMAPK1 | |
| Hexane SCHEMBL23453729 | 0.76 | PDE4D (0.52) | RAB9ANPC1KDM4ELMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4316492-B1 | COMBINATION OF A MULTIKINASE INHIBITOR WITH A PD-1/PD-L1 ANTIBODY AND USES THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-3447056-B1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20250082650-A1 | COMBINED USE OF MULTIKINASE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-03-13 | — | — | US | disclosed |
| EP-4316492-A1 | COMBINED USE OF MULTIKINASE INHIBITOR | Transthera Sciences (Nanjing), Inc. (CN) | 2024-02-07 | — | — | EP | disclosed |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| WO-2022206758-A1 | COMBINED USE OF MULTIKINASE INHIBITOR | 药捷安康(南京)科技股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-115120598-A | Combined use of multi-kinase inhibitors | 药捷安康(南京)科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210130354-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210130354-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10889586-B2 | Multi-kinase inhibitor compound, and crystal form and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-10889586-B2 | Multi-kinase inhibitor compound, and crystal form and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-20190152972-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152972-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10208042-B1 | Multi-kinase inhibitor compound, and crystal form and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2019-02-19 | — | — | US | disclosed |
| US-10208042-B1 | Multi-kinase inhibitor compound, and crystal form and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2019-02-19 | — | — | US | disclosed |
| US-20190040064-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190040064-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130354-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | MAP2K5, MAP3K1, MAP3K19 | RAB9A 1008/4885NPC1 3734/4885KDM4E 597/4885 |
| US-20190152972-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | MAP3K1, MAP2K5, MAP3K5 | RAB9A 1153/4885NPC1 3436/4885KDM4E 500/4885 |
| US-10889586-B2 | Multi-kinase inhibitor compound, and crystal form and use thereof | MAP2K5, MAP3K1, MAP3K7 | RAB9A 1294/4885NPC1 3489/4885KDM4E 494/4885 |
| US-20250082650-A1 | COMBINED USE OF MULTIKINASE INHIBITOR | PDCD1, CD274, PDCD1LG2 | RAB9A 2171/4885NPC1 3745/4885KDM4E 708/4885 |
| US-20190040064-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | MAP2K5, MAP3K1, MAP3K7 | RAB9A 1319/4885NPC1 3504/4885KDM4E 492/4885 |
| US-10208042-B1 | Multi-kinase inhibitor compound, and crystal form and use thereof | MAP2K5, MAP3K1, MAP3K7 | RAB9A 1294/4885NPC1 3489/4885KDM4E 494/4885 |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | MAP3K1, MAP3K5, MAP3K2 | RAB9A 1316/4885NPC1 4184/4885KDM4E 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.